KROS
Keros Therapeutics Inc
11.60$
+0.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +13.4% | +31.3% | -6.3% | +27.3% | +6.3% | +27.4% | -3.5% | -1.9% | -54.5% | -7.6% | -7.9% | |
| – | +14.1% | +33.4% | -6.6% | +27.6% | +6.7% | +29.0% | -3.5% | -1.8% | -56.1% | -7.8% | -8.2% | |
| – | +15.0% | +33.6% | -8.3% | +30.8% | +5.5% | +28.7% | -4.2% | +0.5% | -58.6% | -2.1% | -8.5% | |
| – | +15.0% | +33.6% | -8.3% | +30.8% | +5.5% | +28.7% | -4.2% | +0.5% | -58.6% | -2.1% | -8.5% | |
| – | +21.5% | +63.0% | -24.4% | +43.0% | +131.7% | +334.8% | -8.4% | -68.6% | +14.5% | -53.5% | -7.0% | |
| – | -8.3% | -100.0% | +0.0% | – | – | – | – | – | – | – | – | |
| – | +24.4% | -15.7% | +7.0% | +36.2% | -4.5% | +25.6% | -9.4% | -22.3% | -11.0% | -23.6% | -5.2% | |
| – | +45.9% | -23.2% | +13.5% | +36.5% | -5.4% | +43.5% | -11.9% | -30.6% | -15.3% | -37.0% | -5.4% | |
| – | +64.5% | +4.5% | +4.4% | +69.4% | +6.5% | +6.3% | +6.1% | +3.9% | +3.9% | +3.9% | +3.8% | |
| – | +40.9% | -8.5% | +31.1% | -23.8% | -7.6% | +44.2% | -20.6% | -56.4% | -14.4% | -24.1% | +21.6% | |
| – | +12.3% | +36.6% | -7.3% | +26.6% | +7.3% | +27.5% | -3.0% | -0.4% | -56.9% | -5.8% | -8.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.5% | -2.3% | +22.6% | 0.0% | +11.7% | +1.7% | -1.0% | +0.0% | -33.0% | -27.8% | +0.9% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.